知Yizhi Daily
← Back to this edition

Conversations

Daraxonrasib clinical trial shows potential for pancreatic cancer remission

Edition 2026-11-22 · 08:00 Beijing time

An oral KRAS inhibitor called daraxonrasib has drawn attention in an advanced pancreatic cancer trial. Among 61 newly diagnosed patients whose cancer had spread, about 90% saw tumors stop growing, more than 60% saw tumors shrink or disappear, and about 8% had no detectable tumor on CT; the survival rate after one year of treatment was 76.6%. Doctors emphasized it cannot yet be called a cure and longer studies are still needed.

According to the material, daraxonrasib is a KRAS inhibitor that works by locking and shutting down a specific mutation present in most pancreatic cancers that drives tumor growth. The trial subjects were newly diagnosed patients with advanced pancreatic cancer whose disease had spread to other parts of the body. The findings were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The median follow-up in the trial was 18 months. Among the 61 patients, about 90% had tumors that stopped growing, slightly more than 60% had tumors that shrank or disappeared, and about 8% had tumors that were undetectable on CT scans. The material also mentions at the beginning that about one in twelve patients had cancer that became undetectable. One year after starting treatment, 76.6% of patients were still alive, compared with a one-year survival rate of 40% to 45% for patients typically receiving chemotherapy alone.

Pancreatic cancer has a poor prognosis. The material says it has the lowest survival rate among all common cancers in the United Kingdom, and the prognosis is similarly poor worldwide; half of diagnosed patients die within three months, and when the disease has spread to other organs, only about 3% of patients survive five years. Some patients saw no cancer recurrence during the 18-month follow-up period, but whether long-term remission can be achieved still requires longer-term research.

Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center, said this was the result “closest to a cure,” and that he had never seen so many tumors disappear in patients with metastatic pancreatic cancer, while responses were deeper and disease control duration nearly doubled, potentially ultimately translating into longer survival. Michelle Mitchell, chief executive of Cancer Research UK, called it the biggest advance in decades, but also emphasized that more trials are needed to assess whether it can be used by the NHS, and that the therapy also holds promise for other cancers carrying similar KRAS mutations.

Original sources

Hacker News ↗
Back to this editionOpen interactive reader